在动脉样硬化中重新想象瘤药物:新兴机制和治疗潜力
George Liu1, Guillaume De Vlaminck2, Osayamen Atekha1
1Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Biomedicines
|September 27, 2025
概括
动脉样硬化与癌症共享分子通路,这表明癌症药物可能治疗血管疾病. 挑战包括毒性和成本,需要有针对性的方法来有效使用.
科学领域:
- 心血管生物学 心血管生物学
- 在瘤学瘤学.
- 翻译医学是一种翻译医学.
背景情况:
- 动脉样硬化是全球发病率和死亡率的主要原因之一.
- 它涉及脂质积累,炎症和血管重塑.
- 越来越多地认识到与癌症共享的分子机制.
研究的目的:
- 探索动脉样硬化和癌症生物学之间的重叠.
- 为了研究癌症治疗动脉样硬化的潜在重新利用.
- 确定治疗翻译的挑战和未来方向.
主要方法:
- 对共享分子通路的临床前数据的审查.
- 对动脉样硬化调节的潜在瘤治疗方法的分析.
- 确定临床翻译的障碍.
主要成果:
- 动脉样硬化和癌症具有共同的特征,如持续的增殖和免疫逃避.
- 临床前研究表明,对癌症药物的重新定位有希望.
- 存在重大障碍,包括药物毒性,安全性,监管和成本.
结论:
- 动脉样硬化和癌症之间的分子并行提供了新的治疗机会.
- 克服转化障碍对于将癌症药物整合到血管疾病治疗中至关重要.
- 未来的研究应该专注于生物标志物,剂量优化和有针对性的输送.
相关概念视频
Atherosclerosis III: Management
321
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
321
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Atherosclerosis I: Introduction
923
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
923
Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K


